web analytics
10.4 C
Munich
Monday, October 25, 2021

The Rise of Quanta, Inc. (OTC PINK: QNTA) As its Rhopalurus Princeps Scorpion Peptide Escozine Gains Traction

Quanta, Inc. (OTC PINK: QNTA) has been on the move in recent months running northbound off its lows under a nickel to recent highs of $0.21 per share. The stock is quickly emerging as an investors favorite and is currently among the most actively searched and talked about stocks in small caps. Currently under heavy accumulation QNTA is moving steadily northbound with many new investors buying in every day. QNTA is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – a break over $0.21 and its blue skies ahead.  

There is a lot to get excited about on QNTA; The Company’s lead clinical development programs include Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company’s polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. In April the Company reported pre-clinical study results show that the Company’s lead drug candidate Escozine®, when combined with leading chemotherapy agents such as Cyclophosphamide, Etoposide and Cisplatin, has a synergistic effect in killing leukemia and lymphoma cancer cell lines and cancer cells. The Company has an exclusive agreement with the Ministry of Health in the DR where it hopes to have a renewed product registration for Escozine® after having conducted safety studies on over 500 patients. Additionally, the Company has an Investigational New Drug (IND) application on Escozine® with the United States Food and Drug Administration (FDA). 

Quanta, Inc. (OTC PINK: QNTA) is an applied science company, focusing on enhancing energy levels in plant matter to increase performance within the human body. Its proprietary technology uses quantum mechanics to increase bioactivity of targeted molecules to enhance the desired effects. The Company specializes in potentiating rare, naturally occurring elements to create impactful and sustainable healing solutions that are as powerful and predictable as pharmaceutical drugs. Quanta offers its technology as a platform to product makers through distribution channels as well as consumer products. The Company serves brands in cannabis, anti-aging, health and wellness, stress management, pain management, fitness and brain performance enhancement. Quanta’s CBD pain relief rub, is an all-natural CBD topical that consists of 13 natural elements including turmeric, arnica and polarized cannabidiol (CBD), designed to provide relief from pain, inflammation, and stiffness in muscles and joints. Quanta was founded in 2016 and is headquartered in Los Angeles, California. The Company reported revenuers of $1.158 million for 2020 and has a fairly healthy looking balance sheet with just 2.6 million in total liabilities.

Quanta majority owned subsidiary Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products. Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian who pioneered the unlaying polarization technology that makes the Company’s portfolio of pharmaceutical and nutraceutical products so effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio company. The Company’s lead clinical development programs include Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company’s polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. The Company has completed preclinical safety and efficacy research on Escozine® and is pursuing product registration and drug approval in various countries, including the United States and throughout Latin America.  

Escozine® is a polarized solution of the Rhopalurus princeps scorpion peptide owned by Medolife. It is currently undergoing clinical research in the Dominican Republic (DR) as well as the United States for the treatment of cancer and COVID-19. The Company has an exclusive agreement with the Ministry of Health in the DR where it hopes to have a renewed product registration for Escozine® after having conducted safety studies on over 500 patients. Additionally, the Company has an Investigational New Drug (IND) application on Escozine® with the United States Food and Drug Administration (FDA). 

https://twitter.com/alvarojpastor/status/1392508177447628803

To Find out the inside Scoop on QNTA subscribe to Microcapdaily.com Right Now by entering your Email in the box below

QNTA

In April the Company reported pre-clinical study results show that the Company’s lead drug candidate Escozine®, when combined with leading chemotherapy agents such as Cyclophosphamide, Etoposide and Cisplatin, has a synergistic effect in killing leukemia and lymphoma cancer cell lines and cancer cells. CEO Dr. Arthur Mikaelian stated: “Chemotherapy is by far the most used cancer therapeutic and physicians’ main line of defense in curving the second leading cause of death in the world, and we just proved that our drug increases its effectiveness. While we have continued to study Escozine’s efficacy in killing cancer cells as a standalone therapeutic, applying it as synergistic medicine to current cancer treatment regimens such as chemotherapy could be the faster route to getting the power of Escozine to cancer patients who need it most. We are humbled to have worked with such a renowned research organization and could not be more excited by these results. After proving that Escozine was able to kill cancer cells and cell lines in up to 95 percent of samples, adding this result to our arsenal of clinical data illustrates the true potential of Escozine as a cancer fighting drug. We hope to use this data to push forward our clinical program on Escozine into human trials in both the United States and the Dominican Republic in short order.” 

Through its subsidiary QuantRx, Medolife manufactures and distributes consumer wellness products in high-impact consumer areas such as pain relief, beauty, and general wellness. QuantRx products are designed using Dr. Mikaelian’s polarization technology, which applies advances in quantum biology to increase the potency of active ingredients. Ultimately, Quanta’s mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste, and facilitate healthier, more sustainable consumption. 

Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Medolife has the opportunity to upend how commercial and pharmaceutical products are made and increase their benefits, while decreasing their chemical concentration. 

Last week Medolife Rx reported it has secured a new extraction facility in the Dominican Republic (DR) as well as onboarded scientific staff in order to increase production of Escozine® to meet rising demand following the Company’s recent product registration as a natural alternative cancer treatment. 

As announced, the Company has been scaling production of its lead drug candidate Escozine®, which is derived from peptides found in scorpions that are then polarized through a patented process to increase efficacy. The peptides are extracted from the scorpions in a safe and humane way through a scientific process conducted in a clean laboratory setting. As such, the Company worked with the Ministry of Environment and Natural Resources in the DR to identify and garner the necessary approvals for an extraction facility to support this production. After receiving said approvals, the Company has now onboarded a scientific team at the facility who is trained and ready to begin extraction of the peptides. This team will increase Medolife’s current capacity by around ten-fold, with the capability of adding a night shift and later doubling that increase in production. 

Medolife CEO Dr. Arthur Mikaelian stated: “Our goal is to not only sell approved pharmaceutical medicines and functional wellness products, but to own our supply chain, which is rare in our space, and this facility adds to that construct. Paired with our first-of-its-kind scorpion reservation, this extraction facility will allow us to produce the peptides necessary to create most of our pharmaceutical products in-house. That means increased margins and a decreased final cost, creating a larger market opportunity in under-developed or developing nations.” 

For More on QNTA Subscribe Right Now!

QNTA has been on the move in recent months running northbound off its lows under a nickel to recent highs of $0.21 per share. The stock is quickly emerging as an investors favorite and is currently among the most actively searched and talked about stocks in small caps. Currently under heavy accumulation QNTA is moving steadily northbound with many new investors buying in every day. QNTA is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – a break over $0.21 and its blue skies ahead. There is a lot to get excited about on QNTA; The Company’s lead clinical development programs include Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company’s polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. In April the Company reported pre-clinical study results show that the Company’s lead drug candidate Escozine®, when combined with leading chemotherapy agents such as Cyclophosphamide, Etoposide and Cisplatin, has a synergistic effect in killing leukemia and lymphoma cancer cell lines and cancer cells. The Company has an exclusive agreement with the Ministry of Health in the DR where it hopes to have a renewed product registration for Escozine® after having conducted safety studies on over 500 patients. Additionally, the Company has an Investigational New Drug (IND) application on Escozine® with the United States Food and Drug Administration (FDA). We will be updating on QNTA when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with QNTA.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in QNTA either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.